RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Scotia set CXR target price US$75 and rated outperformanceCXR stated that single digit growth in US market is expected. With the acquisition, they have dropped their US exposure from 100% to 40%. In EU they expect to see mid teen growth. These will be done with a combination of price increases, improved marketing of previously under marketed product and new products (60 in all). Since these are established drugs, there is less R&D burden and risk. Pure marketing at a competitive price. I hope that answers your questions.
FootballFan1 wrote:
Since CXR didn't get roasted in front of a U.S Congressional Committee like VRX did, I guess you could say they have stayed out of the (unwelcome) spotlight, but isn't it the case that, like VRX, CXR counts on significant price increases on their drugs as a major driver of earnings and profit...?......How much of CXR's revenue comes from the USA..?....Is / was the USA the most lucrative market in terms of the size of drug price increases for CXR...?......What kind of limits to price increases does CXR experience (or will face) in other countries....?.....Is CXR planning to dedicate more resources to (more expensive) R&D like VRX is planning, or are they still going to go full-bore with simply trying to increase prices on their existing portfolio and spend as little as possible on R&D to bring new drugs to market.....?